Revolo Biotherapeutics Presents New Preclinical Data for '1104 in Acute Respiratory Distress Syndrome Associated With Influenza Infection at the ATS 2023 International Conference
Data continues to demonstrate the broader potential of ‘1104 to avoid and reduce inflammation in multiple models of disease, including allergy and beyond
NEW ORLEANS and CAMBRIDGE, UK,, May 22, 2023 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, today announced new preclinical data discussed in a poster presentation at the American Thoracic Society (ATS) 2023 International Conference. The poster showcases the ability of its immune-resetting drug candidate ‘1104 to inhibit and reduce lung inflammation without immunosuppression in a new model of acute respiratory distress syndrome (ARDS) associated with influenza infection.
“We are pleased with these new results which showcase the potential of ‘1104 to modulate the inflammatory response in the lung in models beyond our lead allergic disease indications,” said Jonathan Rigby, Chief Executive Officer of Revolo. “The data continues to highlight the unique mechanism of action (MOA) of ‘1104, acting ahead of the inflammatory cascade to reset the immune system. As we build on the positive Phase 2a trial data of ‘1104 in eosinophilic esophagitis (EoE) and prepare to release data from our second Phase 2a study of ‘1104 in allergic disease, we continue to evaluate additional potential indications that could benefit from ‘1104’s unique MOA.”
In this model,
As part of the study, mice were infected with influenza A virus (IAV). Three days after infection, animals received either PBS (negative control) or 30µg of polyinosinic-polycytidylic acid (poly I:C) to exacerbate influenza-induced lung inflammation. Mice were treated with ‘1104 (80 or 800 µg/Kg) or PBS 15 minutes before and 24 hours after poly I:C or with dexamethasone at 10mg/kg (treatment control), 1 hour before and 24 hours after the poly I:C challenge. At 48 hours after the poly I:C challenge, bronchoalveolar lavage fluid was collected to conduct differential cell counts and to measure cytokines. Lung tissue was also collected to determine the viral load.
For further information, please visit www.revolobio.com.